AdnaGen

AdnaGen is a privately held biotechnology research and development company based in Langenhagen, Germany. AdnaGen was recently acquired by OncoVista (2009).

AdnaGen offers test systems enabling physicians to effect an individualised treatment of cancer. AdnaGen's core expertise is the development of innovative tumour diagnostics by utilizing its proprietary technology for the detection and molecular analysis of circulating tumour cells (CTCs).

Kits for breast (AdnaTest BreastCancer) and colon (AdnaTest ColonCancer) as well as an add-on kit for the detection of steroid receptors (AdnaTest ER/PR) on CTCs are CE-marked and currently marketed in Europe. A kit for the detection of CTCs in ovarian cancer will be available soon.

Further developments include several molecular markers that reveal the presence of potential therapeutic targets on CTCs. The analysis of expression profiles of these markers is also contributing to a better understanding of the biology of CTCs.

To this end, AdnaGen has developed assays for the determination of epithelial-mesenchymal transition (EMT) and stem cell markers (patent pending) that can be used in combination with the AdnaTest BreastCancer. Clinical results are available that underline the clinical importance of these markers. AdnaGen is ISO 9001 and EN 13485 certified.

Website: www.adnagen.com